DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
Iperoxo (HB9785)
Description:Potent muscarinic acetylcholine receptor superagonist. Also binds the hM3R-miniGq receptor.
-
Ivermectin (IVM) (HB1958)
Description:α7 nicotinic acetylcholine receptor positive allosteric modulator. Activates GluCI/GlyCI chemogenetic channels. Shows antiviral activity.
Purity:>95%
-
JHU37152 (DREADD ligand) (HB6252)
Description:Novel DREADD agonist with high affinity and potency for hM3Dq and hM4Di. Active in vivo. Freebase.
Purity:>98%
- Description:
Novel DREADD agonist with high affinity and potency for hM3Dq and hM4Di. Active in vivo. Water soluble.
Purity:>98%
-
JHU37160 (DREADD ligand) (HB6260)
Description:Novel DREADD agonist with high affinity and potency for hM3Dq and hM4Di. Active in vivo. Freebase.
Purity:>98%
- Description:
Novel DREADD agonist with high affinity and potency for hM3Dq and hM4Di. Active in vivo. Water soluble.
Purity:>98%
-
LIH383 (HB9242)
Description:Potent and selective ACKR3 (CXCR7) agonist. Potentiates opioid peptide activity.
-
Loperamide hydrochloride (HB0385)
Description:Potent, selective µ-opioid receptor agonist
Purity:>99%
